210 studies found for:    regeneron
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
2 Completed A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Condition: Sciatica
Interventions: Drug: REGN475;   Drug: Placebo Injection
3 Active, not recruiting Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
4 Recruiting Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
Conditions: Osteoarthritis, Knee;   Osteoarthritis, Hip
Interventions: Drug: REGN475;   Drug: Placebo
5 Recruiting Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: REGN2176-3;   Drug: Intravitreal Aflibercept Injection (IAI)
6 Recruiting A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
Condition: Atopic Dermatitis
Intervention: Drug: Dupilumab
7 Recruiting Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Condition: Advanced Malignancies
Interventions: Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide
8 Recruiting Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo
9 Recruiting Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Condition: Respiratory Syncytial Virus Infections
Intervention: Drug: REGN2222
10 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: REGN1979 multiple dose levels
11 Recruiting Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: REGN1193;   Drug: Placebo
12 Recruiting Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
13 Recruiting Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Drug: REGN1500
14 Recruiting Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: dupilumab;   Drug: placebo
15 Recruiting Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
Conditions: Neovascular Age-Related Macular Degeneration;   Diabetic Macular Edema
Interventions: Drug: REGN910-3;   Drug: REGN910;   Drug: Intravitreal Aflibercept Injection (IAI)
16 Recruiting Study to Assess the Safety and Tolerability of Single Doses of REGN1500
Condition: Hypertriglyceridemia
Interventions: Drug: REGN1500;   Drug: placebo
17 Unknown  The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Intervention: Drug: Intravitreal Aflibercept Injection
18 Completed VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: ziv-aflibercept
19 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept
20 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years